The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Radioiodine Treatment of Hyperthyroidism--Prognostic Factors for Outcome
Abstract
There is little consensus regarding the most appropriate dose regimen for radioiodine (131I) in the treatment of hyperthyroidism. We audited 813 consecutive hyperthyroid patients treated with radioiodine to compare the efficacy of 2 fixed-dose regimens used within our center (185 megabequerels, 370 megabequerels) and to explore factors that may predict outcome. Patients were categorized into 3 diagnostic groups: Graves' disease, toxic nodular goiter, and hyperthyroidism of indeterminate etiology. Cure after a single dose of 131I was investigated and defined as euthyroid off all treatment for 6 months or T4 replacement for biochemical hypothyroidism in all groups. As expected, patients given a single dose of 370 megabequerels had a higher cure rate than those given 185 megabequerels, (84.6% vs. 66.6%, P < 0.0001) but an increase in hypothyroidism incidence at 1 yr (60.8% vs. 41.3%, P < 0.0001). There was no difference in cure rate between the groups with Graves' disease and those with toxic nodular goiter (69.5% vs. 71.4%; P, not significant), but Graves' patients had a higher incidence of hypothyroidism (54.5% vs. 31.7%, P < 0.0001). Males had a lower cure rate than females (67.6% vs. 76.7%, P = 0.02), whereas younger patients (<40 yr) had a lower cure rate than patients over 40 yr old (68.9% vs. 79.3%, P < 0.001). Patients with more severe hyperthyroidism (P < 0.0001) and with goiters of medium or large size (P < 0.0001) were less likely to be cured after a single dose of 131I. The use of antithyroid drugs, during a period 2 wk before or after 131I, resulted in a significant reduction in cure rate in patients given 185 megabequerels 131I (P < 0.01) but not 370 megabequerels. Logistic regression analysis showed dose, gender, goiters of medium or large size, and severity of hyperthyroidism to be significant independent prognostic factors for cure after a single dose of 131I. We have demonstrated that a single fixed dose of 370 megabequerels 131I is highly effective in curing toxic nodular hyperthyroidism as well as Graves' hyperthyroidism. Because male patients and those with more severe hyperthyroidism and medium or large-sized goiters are less likely to respond to a single dose of radioiodine, we suggest that the value of higher fixed initial doses of radioiodine should be evaluated in these patient categories with lower cure rates.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
THE SPECTRUM OF THYROID DISEASE IN A COMMUNITY: THE WHICKHAM SURVEY
TUNBRIDGE, W. M. G., EVERED, D. C., HALL, R., APPLETON, D., BREWIS, M., CLARK, F., EVANS, J. G., YOUNG, E., BIRD, T., & SMITH, P. A. (1977) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1977.tb01340.x · Cited by 2,674
The incidence of thyroid disorders in the community: a twenty-year follow-up of the Whickham Survey
Vanderpump, M. P. J., Tunbrldge, W. M. G., French, J. M., Appleton, D., Bates, D., Clark, F., Evans, J. G., Hasan, D. M., Rodgers, H., Tunbridge, F., et al. (1995) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1995.tb01894.x · Cited by 2,432
Werner, S. C. (1977) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-44-1-203 · Cited by 466
The Management of Hyperthyroidism
Wood, A. J. J., & Franklyn, J. A. (1994) · New England Journal of Medicine · doi:10.1056/nejm199406163302407 · Cited by 306
VITTI, P., RAGO, T., CHIOVATO, L., PALLINI, S., SANTINI, F., FIORE, E., ROCCHI, R., MARTINO, E., & PINCHERA, A. (1997) · Thyroid · doi:10.1089/thy.1997.7.369 · Cited by 293
Age and Gender Predict the Outcome of Treatment for Graves' Hyperthyroidism
Allahabadia, A. (2000) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.85.3.1038 · Cited by 286
Self-citationFranklyn, J. A., Maisonneuve, P., Sheppard, M., Betteridge, J., & Boyle, P. (1999) · The Lancet · doi:10.1016/s0140-6736(98)12295-x · Cited by 243
Long-Term Follow-up Study of Compensated Low-Dose131I Therapy for Graves' Disease
Sridama, V., McCormick, M., Kaplan, E. L., Fauchet, R., & DeGroot, L. J. (1984) · New England Journal of Medicine · doi:10.1056/nejm198408163110702 · Cited by 190
Reinwein, D. (1993) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.76.6.1516 · Cited by 180
PETERS, H., FISCHER, C., BOGNER, U., REINERS, C., & SCHLEUSENER, H. (1995) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.1995.tb01547.x · Cited by 174
Is calculation of the dose in radioiodine therapy of hyperthyroidism worth while?
Jarløv, A. E., Hegedüst, L., Kristensen, L. Ø., Nygaard, B., & Hansen, J. (1995) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1995.tb02039.x · Cited by 155
Imseis, R. E., VanMiddlesworth, L., MASSIE, J. D., Bush, A. J., & Vanmiddlesworth, N. R. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.83.2.4538 · Cited by 147
Heward, J. M., Allahabadia, A., Daykin, J., et al. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.83.10.5137 · Cited by 140
Self-citationLong‐term follow‐up of treatment of thyrotoxicosis by three different methods
Franklyn, J. A., Daykin, J., Drolc, Z., Farmer, M. J., & Sheppard, M. C. (1991) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1991.tb01738.x · Cited by 139
Success Rate of Radioiodine Therapy in Graves' Disease: The Influence of Thyrostatic Medication
Sabri, O., Zimny, M., Schulz, G., Schreckenberger, M., Reinartz, P., Willmes, K., & Buell, U. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.4.5588 · Cited by 126
Optimal iodine-131 dose for eliminating hyperthyroidism in Graves' disease.
Nordyke, R. A., & Gilbert, F. I. (1991) · PubMed · Cited by 125
Solitary autonomously functioning thyroid lesions
Hamburger, J. I. (1975) · The American Journal of Medicine · doi:10.1016/0002-9343(75)90630-0 · Cited by 112
Benker, G., REINWEIN, D., Kahaly, G., Tegler, L., Alexander, W. D., Faßbinder, J., & Hirche, H. (1998) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1998.00554.x · Cited by 108
TREATMENT OF HYPERTHYROIDISM WITH RADIOACTIVE IODINE
Kaplan, M. M., Meier, D. A., & Dworkin, H. J. (1998) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/s0889-8529(05)70307-8 · Cited by 106
Marcocci, C., Gianchecchi, D., Masini, I., Golia, F., Ceccarelli, C., Bracci, E., Fenzi, G., & Pinchera, A. (1990) · Journal of Endocrinological Investigation · doi:10.1007/bf03348615 · Cited by 89
Catargi, B., Leprat, F., Guyot, M., Valli, N., Ducassou, D., & Tabarin, A. (1999) · European Journal of Endocrinology · doi:10.1530/eje.0.1410117 · Cited by 89
JARLØV, A. E., NYGAARD, B., HEGEDÜS, L., HARTLING, S. G., & HANSEN, J. M. (1998) · Thyroid · doi:10.1089/thy.1998.8.393 · Cited by 86
Iodine‐131 treatment of hyperthyroidism: current issues
Farrar, J., & Toft, A. D. (1991) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1991.tb03523.x · Cited by 68
PLACE OF RADIOACTIVE IODINE IN TREATMENT OF THYROTOXICOSIS
Hennemann, G., Krenning, E. P., & Sankaranarayanan, K. (1986) · The Lancet · doi:10.1016/s0140-6736(86)91675-2 · Cited by 61
OUTCOME FOLLOWING STANDARDIZED 185 MBq DOSE 131I THERAPY FOR GRAVES' DISEASE
Watson, A., Brownlie, B. E. W., Frampton, C. M., Turner, J. G., & Rogers, T. G. H. (1988) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1988.tb03683.x · Cited by 57
Thyroid cancer prevalence after radioiodine treatment of hyperthyroidism.
Angusti, T., Codegone, A., Pellerito, R. E., & Favero, A. (2000) · PubMed · Cited by 53
Age‐Related Therapeutic Response to Antithyroid Drug in Patients with Hyperthyroid Graves' Disease
Yamada, T., Aizawa, T., Koizumi, Y., Komiya, I., Ichikawa, K., & Hashizume, K. (1994) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1994.tb04973.x · Cited by 47
Subclinical Hyperthyroidism -- Just a Low Serum Thyrotropin Concentration, or Something More?
Utiger, R. D. (1994) · New England Journal of Medicine · doi:10.1056/nejm199411103311909 · Cited by 47
Radioiodine therapy compared in patients with toxic nodular or Graves' hyperthyroidism
Franklyn, J. A., Daykin, J., Holder, R. L., & Sheppard, M. C. (1995) · QJM · doi:10.1093/oxfordjournals.qjmed.a069043 · Cited by 46
Blahd, W. H., & Hays, M. T. (1972) · Archives of Internal Medicine · doi:10.1001/archinte.1972.00320010037002 · Cited by 42
Davies, P. H. O., Franklyn, J., Daykin, J., & Sheppard, M. C. (1992) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.74.5.1569166 · Cited by 40
The Autonomous Functioning Thyroid Nodule: Therapeutic Considerations
Miller, J. M., & Block, M. A. (1968) · Archives of Surgery · doi:10.1001/archsurg.1968.01330210064011 · Cited by 31
Thionamides Alter the Efficacy of Radioiodine Treatment in Patients With Gravesʼ Disease
Koroscil, T. M. (1995) · Southern Medical Journal · doi:10.1097/00007611-199508000-00007 · Cited by 30
Low-Dose 131 I in Treatment of Graves' Disease
Lowdell, C. P., Spathis, G. S., Cosgrove, D. O., et al. (1985) · Journal of the Royal Society of Medicine · doi:10.1177/014107688507800305 · Cited by 22
Cited by
Thyroid Function and Human Reproductive Health
Krassas, G. E., Poppe, K., & Glinoer, D. (2010) · Endocrine Reviews · doi:10.1210/er.2009-0041 · Cited by 1,223
Cooper, D. S. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14073-1 · Cited by 386
Epidemiology and prevention of clinical and subclinical hypothyroidism.
Vanderpump, M. P. J., & Tunbridge, W. M. G. (2002) · Thyroid · doi:10.1089/105072502761016458 · Cited by 347
Bonnema, S. J., & Hegedüs, L. (2012) · Endocrine Reviews · doi:10.1210/er.2012-1030 · Cited by 339
Bogazzi, F., Giovannetti, C., Fessehatsion, R., Tanda, M. L., Campomori, A., Compri, E., Rossi, G., Ceccarelli, C., Vitti, P., Pinchera, A., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-1655 · Cited by 88
Metadata
- Authors
- Allahabadia, A.
- Venue
- Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2001-08-01
- Volume
- 86
- Issue
- 8
- Pages
- 3611-3617
- ISSN
- 0021-972X (ISSN-L)
- OpenAlex
- W2034289621
- Cited by
- 264
- References
- 34
- FWCI
- 7.05
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.